The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

被引：0
|
作者：
Browne, Iseult
Pascual, Javier
Cutts, Rosalind
Kingston, Belinda
Hrebien, Sarah
Kilburn, Lucy
Pearson, Alex
Moretti, Laura
Wardley, Andrew
Macpherson, Iain
Baird, Richard
Roylance, Rebecca
Faull, Iris
Banks, Kimberly C.
Garcia-Murillas, Isaac
Bliss, Judith
Ring, Alistair
Turner, Nicholas
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS06-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS06-04
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis
    Telli, M. L.
    McMillan, A.
    Ford, J. M.
    Richardson, A. L.
    Silver, D. P.
    Isakoff, S. J.
    Kaklamani, V. G.
    Gradishar, W.
    Stearns, V.
    Connolly, R. M.
    Loibl, S.
    Elkin, E. P.
    Timms, K.
    Hartman, A-R
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
  • [32] Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)
    Wardley, Andrew M.
    Kilburn, Lucy
    Kernaghan, Sarah
    Macpherson, Iain
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Bliss, Judith M.
    Ring, Alistair
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    Kyte, Jon Amund
    Rossevold, Andreas H.
    Andresen, Nikolai K.
    Bjerre, Christina Annette
    Gilje, Bjornar
    Jakobsen, Erik Hugger
    Raj, Sunil Xavier
    Falk, Ragnhild Sorum
    Borgen, Elin
    Jahr, Thea
    Garred, Oystein
    Lomo, Jon
    Mathiesen, Randi Margit
    Naume, Bjorn
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Results From ALICE: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 9
  • [35] Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial
    Jensen, J. Bjerggaard
    Birkenkamp-Demtroder, K.
    Nordentoft, I.
    Milling, R. V.
    Korner, S. K.
    Brandt, S. B.
    Knudsen, M.
    Lam, G. W.
    Dohn, L. H.
    Fabrin, K.
    Carus, A.
    Petersen, A.
    Joensen, U. N.
    Pappot, H.
    Holt, P. S.
    Jensen, N. V.
    Agerbaek, M.
    Dyrskjot, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1133 - S1133
  • [36] Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials
    Furlanetto, J.
    Denkert, C.
    Untch, M.
    Sinn, B.
    Lederer, B.
    Schneeweiss, A.
    Mueller, V.
    van Mackelenbergh, M.
    Stickeler, E.
    Fasching, P. A.
    Schem, C.
    Karn, T.
    Marme, F.
    Nekljudova, V.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S27 - S28
  • [37] Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial
    Massa, C.
    Schneeweiss, A.
    Karn, T.
    Hanusch, C. A.
    Blohmer, J-U
    Fasching, P. A.
    Jackisch, C.
    van Mackelenbergh, M.
    Marme, F.
    Mueller, V.
    Schem, C.
    Stickeler, E.
    Huober, J.
    Weber, K. E.
    Untch, M.
    Denkert, C.
    Loibl, S.
    Mueller, A.
    Biehl, K.
    Seliger, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC)
    Vidula, Neelima
    Juric, Dejan
    Niemierko, Andrzej
    Spring, Laura
    Moy, Beverly
    Malvarosa, Giuliana
    Yuen, Megan
    Habin, Karleen R.
    Shin, Jennifer Adrienne
    Peppercorn, Jeffrey M.
    Isakoff, Steven J.
    Ellisen, Leif W.
    Iafrate, A. John
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients
    Lim, J.
    Lee, K-H
    Min, A.
    Kim, S-G
    Kim, J-E
    Kim, T-Y
    Han, S-W
    Oh, D-Y
    Kim, T-Y
    Lim, S-A
    CANCER RESEARCH, 2017, 77
  • [40] A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC
    Damodaran, S.
    Symmans, F.
    Helgason, T.
    Mittendorf, E. A.
    Tripathy, D.
    Hess, K.
    Litton, J.
    Moulder, S.
    ANNALS OF ONCOLOGY, 2017, 28
12345